ArticleSubstance abuse treatment, prevention, and policy2026
Higher risk cannabis use indicators among people living in Canada: a cross-sectional study examining the association with socio-demographic and socio-economic factors.
Article in Substance abuse treatment, prevention, and policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in hospitalizations for cannabinoid hyperemesis syndrome in Canada, 2016-17 to 2024-25.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2018, the Cannabis Act regulated the production and sale of cannabis for non-medical purposes in Canada. With the aim of continuing to protect the public health and safety of Canadians as the legal cannabis market matures, we conducted a thorough data disaggregation to identify segments of the cannabis consumer base in Canada who are more likely to engage in ‘higher risk’ cannabis use behaviours. The analysis also aligned with the Canadian federal department of health’s Sex- and Gender-Based Analysis Plus Action Plan.
methodsParticipants were respondents from the 2023 and 2024 cycles of the Canadian Cannabis Survey who reported consuming cannabis in the previous 12 months (n = 7,238). Sixteen higher risk cannabis use outcomes were identified, along with 11 socio-demographic/socio-economic characteristics (herein ‘covariates’). Outcomes were arranged in four categories: heavy cannabis consumption; use of higher risk cannabis products; negative effects of cannabis use on one’s life; and threats to personal or public safety. Prevalence of each outcome was estimated among past 12-month consumers. For each outcome, adjusted logistic regression models tested differences between subgroups for each covariate. After Bonferroni correction for multiple comparisons, a threshold of p < 0.003 was used.
resultsOver three-quarters (78%) of consumers engaged in at least one higher risk outcome (mean = 2.9, SD = 2.8). After adjustment, models revealed that several subgroups tended to engage in higher risk outcomes. These included younger people, males, those reporting lower education and household income levels, and those who reported having poor/fair mental health. There were also higher rates of certain higher risk outcomes among specific ethnic groups and sexual and gender minorities, but these differences became non-significant in adjusted models.
conclusionsStudy results may be used to identify subgroups of cannabis consumers in Canada who are more likely to engage in higher risk cannabis behaviours and who may benefit from more targeted public education or harm reduction initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.